97 results
6-K
RDHL
Redhill Biopharma Ltd.
24 Apr 24
Current report (foreign)
7:05am
being evaluated in the early treatment arm of the study. The primary efficacy assessment in the early treatment indication will be time to sustained
POS AM
RDHL
Redhill Biopharma Ltd.
18 Apr 24
Prospectus update (post-effective amendment)
7:00am
and Boone, LLP.
EXPERTS
The financial statements and management's assessment of the effectiveness of internal control over financial reporting
424B5
RDHL
Redhill Biopharma Ltd.
2 Apr 24
Prospectus supplement for primary offering
4:05pm
by Haynes and Boone, LLP.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial … upon for us by Haynes and Boone, LLP.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over
6-K
RDHL
Redhill Biopharma Ltd.
5 Mar 24
Current report (foreign)
7:01am
as a potential medical countermeasure (MCM) against inhalation Sulfur Mustard exposure. The overall evaluation will also include assessment of opaganib’s
424B5
gjez0gu6y0k61p16
26 Jan 24
Prospectus supplement for primary offering
9:29am
6-K
nqa7 dw3u3nup9mo50
4 Dec 23
Current report (foreign)
7:03am
424B3
fpn n97appi11guq
26 Oct 23
Prospectus supplement
4:52pm
F-3/A
o3r gimwiw
23 Oct 23
Shelf registration (foreign) (amended)
4:06pm
F-3
bqg9 2zewxrq4e
13 Oct 23
Shelf registration (foreign)
8:13am
424B3
s87esdbjm3nk
11 Aug 23
Prospectus supplement
4:52pm
F-3
u6eyhro
4 Aug 23
Shelf registration (foreign)
4:05pm
6-K
hrhpshkhdrr
31 Jul 23
Current report (foreign)
7:03am
424B5
qcheg wzq5wlg
25 Jul 23
Prospectus supplement for primary offering
8:00am
424B5
3anh4 5oigg
3 Apr 23
Prospectus supplement for primary offering
8:49am
424B5
9p4f8y 3fzp7t0d
6 Dec 22
Prospectus supplement for primary offering
6:04am
6-K
EX-1.1
spy4wa7ze5qtgoyqa3vb
5 Dec 22
Current report (foreign)
4:24pm
424B5
pofxuguoxo774 e3e9v
2 Dec 22
Prospectus supplement for primary offering
6:31am